¹¹C-Methionine Uptake Correlates with Combined 1p and 19q Loss of Heterozygosity in Oligodendroglial Tumors

References

1. 1.↵
   1. Reifenberger J,
   2. Reifenberger G,
   3. Liu L,
   4. et al

   . Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994;145:1175–90

   PubMedWeb of Science
2. 2.↵
   1. Cairncross G,
   2. Jenkins R

   . Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma. Cancer J 2008;14:352–57

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Bourne TD,
   2. Schiff D

   . Update on molecular findings, management and outcome in low-grade gliomas. Nat Rev Neurol 2010;6:695–701

   CrossRefPubMed
4. 4.↵
   1. Jenkinson MD,
   2. Smith TS,
   3. Joyce KA,
   4. et al

   . Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours. Neuroradiology 2006;48:703–13

   CrossRefPubMedWeb of Science
5. 5.↵
   1. McGirt MJ,
   2. Chaichana KL,
   3. Attenello FJ,
   4. et al

   . Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63:700–07, author reply 707–08

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Ogawa T,
   2. Inugami A,
   3. Hatazawa J,
   4. et al

   . Clinical positron emission tomography for brain tumors: comparison of fludeoxyglucose F 18 and L-methyl-11C-methionine. AJNR Am J Neuroradiol 1996;17:345–53

   Abstract
7. 7.↵
   1. Kato T,
   2. Shinoda J,
   3. Oka N,
   4. et al

   . Analysis of ¹¹C-methionine uptake in low-grade gliomas and correlation with proliferative activity. AJNR Am J Neuroradiol 2008;29:1867–71

   Abstract/FREE Full Text
8. 8.↵
   1. Kracht LW,
   2. Friese M,
   3. Herholz K,
   4. et al

   . Methyl-[11C]-l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging 2003;30:868–73

   PubMed
9. 9.↵
   1. Maia AC Jr.,
   2. Malheiros SM,
   3. da Rocha AJ,
   4. et al

   . MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. AJNR Am J Neuroradiol 2005;26:777–83

   Abstract/FREE Full Text
10. 10.↵
    1. Akobeng AK

    . Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatr 2007;96:644–47

    PubMedWeb of Science
11. 11.↵
    1. Smith JS,
    2. Perry A,
    3. Borell TJ,
    4. et al

    . Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000;18:636–45

    Abstract/FREE Full Text
12. 12.↵
    1. van den Bent MJ,
    2. Carpentier AF,
    3. Brandes AA,
    4. et al

    . Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006;24:2715–22

    Abstract/FREE Full Text
13. 13.↵
    1. Jenkinson MD,
    2. du Plessis DG,
    3. Smith TS,
    4. et al

    . Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 2006;129:1884–91

    Abstract/FREE Full Text
14. 14.↵
    1. Brown R,
    2. Zlatescu M,
    3. Sijben A,
    4. et al

    . The use of magnetic resonance imaging to noninvasively detect genetic signatures in oligodendroglioma. Clin Cancer Res 2008;14:2357–62

    Abstract/FREE Full Text
15. 15.↵
    1. Walker C,
    2. du Plessis DG,
    3. Fildes D,
    4. et al

    . Correlation of molecular genetics with molecular and morphological imaging in gliomas with an oligodendroglial component. Clin Cancer Res 2004;10:7182–91

    Abstract/FREE Full Text
16. 16.↵
    1. Whitmore RG,
    2. Krejza J,
    3. Kapoor GS,
    4. et al

    . Prediction of oligodendroglial tumor subtype and grade using perfusion weighted magnetic resonance imaging. J Neurosurg 2007;107:600–09

    CrossRefPubMed
17. 17.↵
    1. Lev MH,
    2. Ozsunar Y,
    3. Henson JW,
    4. et al

    . Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol 2004;25:214–21

    Abstract/FREE Full Text
18. 18.↵
    1. Watanabe T,
    2. Nakamura M,
    3. Kros JM,
    4. et al

    . Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Acta Neuropathol 2002;103:267–75

    CrossRefPubMed
19. 19.↵
    1. Nojiri T,
    2. Nariai T,
    3. Aoyagi M,
    4. et al

    . Contributions of biological tumor parameters to the incorporation rate of L: -[methyl-(11)C] methionine into astrocytomas and oligodendrogliomas. J Neurooncol 2009;93:233–41

    CrossRefPubMed
20. 20.↵
    1. Sadeghi N,
    2. Salmon I,
    3. Decaestecker C,
    4. et al

    . Stereotactic comparison among cerebral blood volume, methionine uptake, and histopathology in brain glioma. AJNR Am J Neuroradiol 2007;28:455–61

    Abstract/FREE Full Text
21. 21.↵
    1. Okita Y,
    2. Kinoshita M,
    3. Goto T,
    4. et al

    . (11)C-methionine uptake correlates with tumor cell density rather than with microvessel density in glioma: a stereotactic image-histology comparison. Neuroimage 2010;49:2977–82

    CrossRefPubMed
22. 22.↵
    1. Okubo S,
    2. Zhen HN,
    3. Kawai N,
    4. et al

    . Correlation of L-methyl-11C-methionine (MET) uptake with L-type amino acid transporter 1 in human gliomas. J Neurooncol 2010;99:217–25

    CrossRefPubMed
23. 23.↵
    1. Kapoor GS,
    2. Gocke TA,
    3. Chawla S,
    4. et al

    . Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status. J Neurooncol 2009;92:373–86

    CrossRefPubMed
24. 24.↵
    1. Christov C,
    2. Adle-Biassette H,
    3. Le Guerinel C,
    4. et al

    . Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the vasculature of oligodendrogliomas. Neuropathol Appl Neurobiol 1998;24:29–35

    CrossRefPubMedWeb of Science
25. 25.↵
    1. De Witte O,
    2. Goldberg I,
    3. Wikler D,
    4. et al

    . Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg 2001;95:746–50

    PubMedWeb of Science
26. 26.↵
    1. Megyesi JF,
    2. Kachur E,
    3. Lee DH,
    4. et al

    . Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res 2004;10:4303–06

    Abstract/FREE Full Text